AIkido Pharma Adds Artificial Intelligence Leader to Advisory Board

AIkido Pharma Incorporated (Nasdaq: AIKI) today announced the addition of Andreas Typaldos to the Company's Advisory Board. Mr. Typaldos is a pioneer software and technology entrepreneur, and a private equity investor through a Typaldos Family Office. Also, together with leading scientists in Drug Development at Tufts University and the Fudan University in Shanghai and the Shanghai Center for Drug Discovery and Development, he is on the Board of Directors of Quantitative Cell Diagnostix, www.qcd-x.com, In the past, Mr. Typaldos was founder, founding investor, Board Member, and Chief Executive of a number of software, technology, consulting services, and internet companies, including: Anthony Hayes, CEO of AIkido, noted "Mr. Typaldos is an industry leader in Artificial Intelligence and Machine Learning. His participation on our advisory board will help the Company expand its Artificial Intelligence (AI) and Machine Learning (ML) presence in the drug development field. We are honored he has agreed to lend his expertise and we are excited to work with him."